C3 and metabolic dysfunction-associated steatotic liver disease: In conclusion, plasma AKR1B10 alone and in combination with C3, as a noninvasive biomarker, performed well in the identification of NASH and advanced fibrosis, and is helpful for the longitudinal monitoring of the progression of or improvement in NAFLD.